Candesartan cilexetil in children with hypertension or proteinuria: preliminary data

Simonetti, Giacomo D; von Vigier, Rodo O; Konrad, Martin; Rizzi, Mattia; Fossali, Emilio; Bianchetti, Mario G (2006). Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatric nephrology, 21(10), pp. 1480-2. Berlin: Springer 10.1007/s00467-006-0144-0

Preview

Text s00467-006-0144-0.pdf - Published Version Available under License Publisher holds Copyright. Download (78kB) | Preview

The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood. We were impressed by the neutral taste and the small size of the candesartan cilexetil tablets. This angiotensin II receptor blocker was used during 4 months in 17 pediatric patients (aged 0.5-16, median 4.5 years) with chronic arterial hypertension (n=6), overt proteinuria (n=2), or both (n=9). The initial candesartan dose of 0.23 (0.16-0.28) mg/kg body weight once daily (median and interquartile ranged) was doubled in ten patients [final dose 0.35 (0.22-0.47) mg/kg body weight]. No adverse clinical experiences were noted on candesartan. Candesartan increased plasma potassium by 0.3 (0.0-0.8) mmol/l (P<0.01). In children with arterial hypertension, blood pressure decreased by 9 (3-13)/9 (3-18) mmHg (P<0.01); in those with overt proteinuria the urinary albumin/creatinine ratio decreased by 279 (33-652) mg/mmol (P<0.05). In conclusion, in children candesartan reduces blood pressure and proteinuria with an excellent short-term tolerability profile.

Interest & Impact

Downloads

12 since deposited on 04 Oct 2013
12 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item